Ocugen (OCGN) Long-Term Deferred Tax (2014 - 2015)

Ocugen's (OCGN) quarterly Long-Term Deferred Tax came in at $1.1 million in Q3 2015, up 0.86% on a QoQ basis from $1.0 million in Q2 2015.

Ocugen (OCGN) Long-Term Deferred Tax (2014 - 2015) Analysis & Trends

Ocugen (OCGN) has 2 years of Long-Term Deferred Tax data on file, last reported at $1.1 million in Q3 2015.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $1.1 million in Q3 2015, while the trailing twelve-month figure through Sep 2015 was $1.1 million (changed N/A YoY) and the FY2014 annual result came in at $651000.0, changed N/A from the prior year.
Long-Term Deferred Tax climbed to $1.1 million in Q3 2015, from $1.0 million in the prior quarter.
In the past five years, Long-Term Deferred Tax ranged from a high of $1.1 million in Q3 2015 to a low of $651000.0 in Q4 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Ocugen	457.71 Mn	357.61 Mn	-

Download Data